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A 49-year-old man was referred to our endocrine unitin 2012 with a 15-year history of widespread inca-
pacitating bone and joint pain, which was now causing
marked insomnia. Physical examination revealed proxi-
malmuscleweakness,waddling gait, kyphosis, and a right
metacarpal swelling. Previous biochemical investigations
had revealed a low serum 25-hydroxyvitamin D of 16
ng/mL (reference range [RR], 30–100), elevated serum
alkaline phosphatase (391 U/L; RR, 53–128), normal se-
rumcorrected calcium (9mg/dL;RR,8.5–10.5), anda low
serum phosphorous level (1.8 mg/dL; RR, 2.5–5). He had
previously undergone extensive radiological and rheuma-
tological investigations, whichwere “inconclusive.” Plain
x-ray studies had revealed multiple rib and vertebral frac-
tures. Magnetic resonance imaging of the spine showed
diffuse sclerosis of the vertebral column and pelvic bones.
A Tc-99m-methylene diphosphonate (MDP) bone scan
performed in 2000 had shown increased uptake over the
ribs bilaterally (Figure 1A),whichwas initially reported as
suspicious for metastases. However, extensive cross-sec-
tional imagingwith computed tomography (CT) andmag-
netic resonance imaging failed to identify an underlying
primary lesion. Before the current presentation, he was
treated with multiple analgesics, calcium, phosphorous,
and calcitriol preparations. However, none of these re-
sulted in any improvement in his symptoms.
Because there were no other systemic/localizing fea-
tures,we considered the possibility of a primarymetabolic
bone disorder. A repeat phosphorus level was persistently
low (1.86 mg/dL), with an inappropriate 24-hour urinary
phosphorus of 745mg/d (RR 1000), and the percentage
tubular reabsorption of phosphate off supplements was
0.68 (RR  0.8). 25-Hydroxyvitamin D (32 ng/mL) and
PTH(49pg/mL;RR,14–72) levelswerenormal, but 1,25-
dihydroxyvitaminDwas inappropriately low (3.5 pg/mL;
RR, 19.6–54.3). In view of this, plasma C-terminal fibro-
blast growth factor 23 (FGF-23) level was measured (Im-
mutopics), and was grossly elevated at 3088 RU/mL (RR,
0–150). A whole-body 18F-fluorodeoxyglucose positron
emission tomography (FDG-PET) scan showed focal
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tracer uptake on the radial and dorsal aspect of the head
of the right second metacarpal (maximum standardized
uptake value [SUVmax] 2.5) (Figure 1, B–D). Histolog-
ical analyses of the surgically resected metacarpal lesion
revealed a phosphaturic mesenchymal cell tumor, mixed
connective tissue variant with negative FGF-23, and so-
matostatin receptor subtype 2A immunostaining (Figure
1, E–G). Despite the latter, FGF-23 levels declined rapidly
to 246 RU/mL on day 6 postoperatively, with progressive
symptom relief, confirming a diagnosis of tumor-induced
osteomalacia (TIO).
In view of persisting (albeit considerably improved)
pain and mild hypophosphatemia (2.4 mg/dL), a repeat
18F-FDG-PET scan was performed in 2013 and showed
low-grade residual uptake over the head of the right sec-
ond metacarpal. After careful discussion with the patient,
a ray amputation of the index finger was performed, with
histology confirming complete excision of the residual tu-
mor.After the secondoperation, FGF-23 levels dropped to
152 RU/mL, but the hypophosphatemia persisted. His
pain improved, althoughhedescribedongoingmild symp-
toms. Several months later, the patient reported an in-
crease in the intensity of his bone pain. He had persistent
hypophosphatemia with rising FGF-23 levels (224.5 RU/
mL). In 2015, a whole-body 68Ga-DOTANOC-PET scan
was performed, which revealed no uptake at the site of the
previous surgery. However, a left nasal cavity lesion
(2.9 2.0 cm) (Figure 1, H and I) with avid tracer uptake
(SUVmax, 3.79) was seen. Retrospectively, this lesion
could be seen on the 18F-FDG-PET, although at that time
the relatively low level of tracer uptake was not felt to be
significant. However, axial reconstruction clearly shows
the lesion (Figure 1J). Further reviewof themorehistorical
imaging suggested that this was also probably visible on
the original Tc-99m-MDP bone scan (Supplemental Fig-
ure 1, A and B). Transnasal endoscopic resection of the
nasal lesion revealed a predominant, phosphaturic mes-
enchymal cell tumor (Figure 1, K and L) with negative
Figure 1. A, Tc-99m-MDP bone scan showing increased tracer uptake at multiple sites. B, Whole-body 18F-FDG-PET scan revealing FDG avid soft
tissue thickening over the radial and dorsal aspect of the head of the right second metacarpal (SUVmax  2.5). C and D, Fused 18F-FDG-PET and
CT of the right hand in sagittal (C) and coronal (D) planes. E, Histological examination of metacarpal lesion showing diffuse proliferation of bland
tumor cells in a patternless arrangement around vessels (F) with bluish smudgy matrix. G, Vimentin positivity on immunohistochemistry. H, Whole-
body Ga-68-DOTANOC-PET scan showing avid tracer uptake within left nasal cavity lesion (2.9  2.0 cm;, SUVmax, 3.9). I, Fused Ga-68
DOTANOC PET and CT scan head. J, 18F-FDG-PET SPECT CT head axial imaging demonstrates the left nasal cavity lesion with a low SUV uptake
(SUV max  2.1). K, Histological examination of nasal lesion showing bland tumor cells with fibromyxoid stroma, hemangiopericytomatous pattern
of vasculature (arrow). L, Smudgy matrix (arrow). M, Immunohistochemistry shows strong positive staining for somatostatin receptor subtype 2 A
(SSTR2A). N, Graph depicting the trends in FGF-23 levels over time.
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FGF-23 immunostaining but positive somatostatin recep-
tor subtype2A immunostaining (Figure1M), suggestiveof
amultifocal TIO. Postoperatively, FGF-23 levels returned
to normal within 48 hours of surgery (64.6 RU/mL), and
they currently remain within the RR (50.3 RU/mL) at 3
months, with normalization of phosphorous levels (4.2
mg/dL) and, for the first time, complete resolution of his
symptoms.
Tumors that secrete phosphaturic factors/phospha-
tonins (eg, FGF-23) are usually benign and are the pre-
dominant cause of TIO or oncogenic osteomalacia. As in
our patient, the resulting hypophosphatemia can cause
debilitating pain. Complete resection of a unifocal tumor
typically leads to full resolution of symptoms. However,
localization of these tumors is often difficult due to their
small size and diverse locations (limb extremities to the
head, including soft tissues, bones, sinuses, brain). Sys-
tematic physical examination, combined with cross-sec-
tional and functional imaging is essential for localization.
Among functional scans, some studies have shown soma-
tostatin receptor ligand-based imaging [eg, 111Indium-Oc-
treotide single photon emission CT (SPECT) (1) 99Tc-
HYNIC-TOC SPECT (2), and Gallium-based 68Ga-
DOTA-TATE PET (2–5)] to be better for identifying
phosphaturic mesenchymal cell tumor in comparison to
other imagingmodalities such as 18F-FDG-PET. In a large
case series, Chong et al (1) showed that among 19 patho-
logically confirmed TIO subjects, 18 were octreo-SPECT
scan-positive (sensitivity, 0.95; specificity, 0.64; positive
predictive value, 0.82; and negative predictive value,
0.88), and 14 of 16 confirmed TIO subjects were FDG-
PET-positive (sensitivity, 0.88; specificity, 0.36; positive
predictive value, 0.62; and negative predictive value,
0.50). In addition, in a small number of subjects, 68Ga-
DOTA-TATE/DOTANOC PET has localized TIOs that
were not previously identified with 18F-FDG-PET (2) and
111Indium-Octreotide SPECT imaging (3). In our case, the
intense brain uptake of 18F-FDG-PET obscured the lesion
in the nasal cavity (Figure 1B), and it was only on retro-
spective review of axial imaging that the lesion was noted
(Figure 1J).
Occasionally, evenwith the best efforts to localize these
tumors, they may remain elusive (“a needle in the hay-
stack”). In this scenario, a combined imaging approach
with structural and nuclear imaging affords the best op-
portunity for localization.Moreover, in the setting ofmul-
tiple suspicious lesions on initial imaging, or with a pos-
sible multifocal TIO similar to our case, an ideal initial
approach retrospectively could have included biopsy of
both the lesions and/or selective venous sampling of
FGF-23 around the sites of the lesions. Selective venous
sampling has been shown to help in tumor localization by
using an FGF-23 venous concentration ratio between the
venous drainage of the tumor bed in comparison to the
general circulation (6). In this way, selective venous sam-
pling can differentiate between a culprit lesion and other
incidental lesions, thereby avoiding unnecessary surgery (6).
Previous reports have always noted complete normal-
ization of hypophosphatemia and FGF-23 levels with suc-
cessful surgery. Inour case, biochemicalnormalizationdid
not happen, despite complete surgical excision of the
metacarpal lesion after the second surgery. Althoughmul-
tifocality is extremely rare and has only previously been
described in fourpatients (7–10), persisting symptomsand
failure of FGF-23 levels to normalize after complete ex-
cision of the metacarpal lesion prompted a detailed re-
evaluation of the case and the adoption of more sensitive
imaging in the form ofGa-68DOTANOCPET. It is likely
that if the latter had been used as the preferred imaging
modality at the time of his referral to our service, then a
structured approach as outlined above, combining selec-
tive venous sampling and biopsy, would potentially have
led to earlier identification of the multifocality, although
still requiring two separate surgical procedures.
This image highlights the importance of a multimodal,
perseverant approach toward the investigation and treat-
ment of patients with persistent unexplained hypophos-
phatemia and chronic bone pain, and it serves as an im-
portant reminder of possible multifocal disease in
unresolved cases of TIO.
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